Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Cardiovascular outcomes
Chronic kidney disease
Heart failure
Renal protection
SGLT2 inhibitors
Type 2 diabetes mellitus
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
accepted:
31
08
2020
pubmed:
10
9
2020
medline:
15
12
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
Initially developed as glucose-lowering drugs, sodium-glucose co-transporter type 2 inhibitors (SGLT2i) have demonstrated to be effective agents for the risk reduction of cardiovascular (CV) events in patients with type 2 diabetes mellitus (T2DM). Subsequently, data has emerged showing a significant CV benefit in patients treated with SGLT2i regardless of diabetes status. Renal protection has been initially evaluated in CV randomized trials only as secondary endpoints; nonetheless, the positive results gained have rapidly led to the evaluation of nephroprotection as primary outcome in the CREDENCE trial. Different renal and vascular mechanisms can account for the CV and renal benefits enlightened in recent literature. As clinical guidelines rapidly evolve and the role of SGLT2i appears to become pivotal for CV, T2DM, and kidney disease management, in this review, we analyze the renal effects of SGLT2, the benefits derived from its inhibition, and how this may result in the multiple CV and renal benefits evidenced in recent clinical trials.
Identifiants
pubmed: 32901315
doi: 10.1007/s10741-020-10024-2
pii: 10.1007/s10741-020-10024-2
pmc: PMC7895775
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
337-345Références
Kidney Int Suppl. 2007 Aug;(106):S27-35
pubmed: 17653207
Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51
pubmed: 24622320
Am J Physiol Renal Physiol. 2020 Apr 1;318(4):F1017-F1029
pubmed: 32116017
J Hypertens. 2020 Aug;38(8):1436-1442
pubmed: 32371764
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Am J Physiol Regul Integr Comp Physiol. 2011 May;300(5):R1009-22
pubmed: 21228342
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
J Diabetes Investig. 2019 May;10(3):760-770
pubmed: 30412655
Diabetes. 2016 May;65(5):1190-5
pubmed: 26861783
Diabetes Obes Metab. 2018 Aug;20(8):1988-1993
pubmed: 29573529
Diabetologia. 2020 Jun;63(6):1128-1140
pubmed: 32236732
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139
pubmed: 30635226
J Am Heart Assoc. 2018 Feb 10;7(4):
pubmed: 29440005
Eur Heart J. 2014 Feb;35(7):455-69
pubmed: 24164864
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Afr J Prim Health Care Fam Med. 2017 Oct 26;9(1):e1-e3
pubmed: 29113441
Lancet Diabetes Endocrinol. 2015 Feb;3(2):148-57
pubmed: 24731670
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31
pubmed: 22238392
J Am Soc Hypertens. 2016 Mar;10(3):271-8
pubmed: 26874564
Circulation. 2019 Apr 23;139(17):2022-2031
pubmed: 30786725
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Physiol Rev. 1994 Oct;74(4):993-1026
pubmed: 7938229
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Drug Discov Today. 2019 Jan;24(1):256-262
pubmed: 30086405
Curr Opin Nephrol Hypertens. 2016 Mar;25(2):81-6
pubmed: 26808705
BMJ Open. 2012 Oct 18;2(5):
pubmed: 23087012
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593
pubmed: 32559474
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617
pubmed: 31196815
Diabetes Care. 2011 Sep;34(9):2015-22
pubmed: 21816980
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621
pubmed: 28666775
Diabetologia. 2018 Oct;61(10):2108-2117
pubmed: 30132036
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F184-F191
pubmed: 28381459
Am J Kidney Dis. 2019 Nov;74(5):713-715
pubmed: 31255334
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Physiol Rev. 2011 Apr;91(2):733-94
pubmed: 21527736
Diabetes Care. 2009 Sep;32(9):1656-62
pubmed: 19528367
N Engl J Med. 2019 Sep 12;381(11):1089-1090
pubmed: 31509685
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):157-167
pubmed: 29981350
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Nat Rev Endocrinol. 2012 Feb 07;8(8):495-502
pubmed: 22310849
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127
pubmed: 30635225
Cardiovasc Diabetol. 2014 Jan 29;13:28
pubmed: 24475922
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):394-404
pubmed: 32402065
J Diabetes Res. 2015;2015:341583
pubmed: 26064978
Diabetes Obes Metab. 2018 Mar;20(3):479-487
pubmed: 29024278
Am J Nephrol. 2019;49(4):331-342
pubmed: 30921791
Diabetes Metab. 2017 Apr;43(2):99-109
pubmed: 28153377
Diabetologia. 2006 Aug;49(8):1761-9
pubmed: 16736131
Circulation. 2020 Sep 15;142(11):1028-1039
pubmed: 32410463
Diabetologia. 2015 Jun;58(6):1183-7
pubmed: 25813214
Am J Nephrol. 2020;51(2):119-129
pubmed: 31910407
Lancet Diabetes Endocrinol. 2015 Dec;3(12):928-9
pubmed: 26590679
Eur J Heart Fail. 2019 Mar;21(3):386-388
pubmed: 30767353
Int J Clin Pract. 2012 May;66(5):446-56
pubmed: 22413962
JACC Basic Transl Sci. 2020 Jan 29;5(2):169-179
pubmed: 32140623
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175
J Hypertens. 2017 Oct;35(10):2059-2068
pubmed: 28598954
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:55-68
pubmed: 32267075